



NORRIS

MEDICINES LIMITED



Factory : Plot No. 801/P, 901/3-5, GIDC Estate, ANKLESHWAR 393 002. (Gujarat)
Regd. Office : Plot No. 801/P, GIDC Estate, ANKLESHWAR 393 002. (Gujarat)
Telephone : (02646) 223462, 227530
Fax : (02646) 250126
E-mail : contact@norrispharma.com
Website : www.norrispharma.com
CIN : L24230MH1990PLC058071

New CIN : L24230GJ1990PLC086581

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED & NINE MONTHS ENDED 31/12/2016

Sr. No.	Particulars	(Rs. In Lacs)					
		Quarter ended			Nine Months ended		Year ended
		31-12-2016 (Unaudited)	30-09-2016 (Unaudited)	31-12-2015 (Unaudited)	31-12-2016 (Unaudited)	31-12-2015 (Unaudited)	31-03-2016 (Audited)
1	Income from Operations						
	(a) Net Sales/ Income from Operations	526.58	664.17	447.86	1608.59	1369.90	1885.63
	(b) Other Operating Income	0.00	0.00	0.00	0.49	9.32	29.68
	Total Income from Operations (Net)	526.58	664.17	447.86	1609.08	1379.22	1915.31
2	Expenses						
	(a) Cost of materials consumed	262.32	349.69	249.92	803.43	725.25	959.36
	(b) Purchase of stock in trade	0.00	0.00	0.00	0.00	0.00	0.00
	(c) Change in inventories of finished goods work in progress and stock-in-trade	-36.74	35.57	-57.89	6.49	-100.82	-29.39
	(d) Employee benefits expense	145.04	139.74	132.24	401.27	359.90	483.53
	(e) Depreciation and amortisation expense	14.50	14.50	31.47	43.50	94.40	59.81
	(f) Other Expense	124.59	116.70	93.80	339.46	274.56	388.69
	Total Expenses	509.71	656.20	449.54	1594.15	1353.29	1862.00
3	Profit / (Loss) from operations before Other Income, Finance Costs and Exceptional Items (1-2)	16.87	7.97	-1.68	14.93	25.93	53.31
4	Other Income	1.21	0.18	2.73	1.58	9.28	0.00
5	Profit / (Loss) from ordinary activities before Finance Costs and Exceptional Items (3 ± 4)	18.08	8.15	1.05	16.51	35.21	53.31
6	Finance Costs	14.16	12.73	27.42	39.04	56.40	67.03
7	Profit / (Loss) from ordinary activities after Finance Costs but before Exceptional Items (5 ± 6)	3.92	-4.58	-26.37	-22.53	-21.19	-13.72
8	Exceptional items	0.00	0.00	0.00	0.00	0.00	0.00
9	Profit / (Loss) from Ordinary activities before Tax (7 ± 8)	3.92	-4.58	-26.37	-22.53	-21.19	-13.72
10	Tax Expense	0.00	0.00	0.00	0.00	0.00	17.50
11	Net Profit / (Loss) from ordinary activities after tax (9 ± 10)	3.92	-4.58	-26.37	-22.53	-21.19	3.78
12	Extraordinary Items (Net of tax expense)	0.00	0.00	0.00	0.00	0.00	0.00
13	Net Profit / (Loss) for the period (11 ± 12)	3.92	-4.58	-26.37	-22.53	-21.19	3.78
14	Share of Profit / (Loss) of Associates	0.00	0.00	0.00	0.00	0.00	0.00
15	Minority Interest	0.00	0.00	0.00	0.00	0.00	0.00
16	Net Profit / (Loss) after taxes, minority interest share of Profit / (Loss) of associates (13 ± 14 ± 15)	3.92	-4.58	-26.37	-22.53	-21.19	3.78
17	Paid-up Equity Share Capital (face value of the share shall be indicated)	992.58	992.58	992.58	992.58	992.58	992.58
18	Reserve excluding revaluation reserves as per balance sheet of previous accounting year	0.00	0.00	0.00	0.00	0.00	0.00
19	Basic and Diluted EPS before & after extraordinary items	0.04	-0.05	-0.26	-0.23	-0.21	0.04

Notes:

- The above Unaudited Financial Results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meeting held on 03.02.2017. Limited review of the above results has been carried out by the Statutory Auditors of the Company.
- The Company is having one segment only and therefore Segmental Reporting is not applicable.
- There are no exceptional/ extraordinary items during the quarter ended 31.12.2016.
- Previous year/period figures have been regrouped/rearranged wherever necessary to make them comparable with current period figures.

Date : 03.02.2017
Place : Ankleshwar



For, Norris Medicines Limited

Vimal D. Shah
Managing Director

LIMITED REVIEW REPORT

To,
The Board of Directors
Norris Medicines Limited
Ankleshwar – Gujarat.

We have reviewed the accompanying statement of unaudited financial results of **Norris Medicines Limited** ("the company") for the period ended 31st December, 2016. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, *Review of Interim Financial Information Performed by the Independent Auditor of the Entity* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.


Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place : BHARUCH

Date : 03rd February, 2017

232, Rangoli Complex,
Station Road,
Bharuch – 392 001
Gujarat.

For, **MINU MODI & CO.**
Chartered Accountants


CA MINU MODI
Proprietor
M. No. 100289
(Firm Reg. No. 119948W)

